Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts

Publication Type:
Journal Article
European Urology, 2019, 76 (5), pp. 693 - 702
Issue Date:
Filename Description Size
1-s2.0-S0302283819306025-main.pdfPublished Version1.57 MB
Adobe PDF
Full metadata record
© 2019 European Association of Urology Two active surveillance risk calculators to predict disease reclassification on prostate biopsy are externally validated by the Movember Foundation's Global Action Plan (GAP3) consortium. They proved to be clinically useful and could reduce unnecessary biopsies, but need recalibration to local settings.
Please use this identifier to cite or link to this item: